NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer

被引：0

作者：

Fehrenbacher, Louis

Jeong, Jong-Hyeon

Rastogi, Priya

Geyer, Charles E.

Paik, Soonmyung

Ganz, Patricia A.

Land, Stephanie R.

Costantino, Joseph P.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, Vallejo, CA USA

[2] Kaiser Permanente Calif, Vallejo, CA USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA

[4] NSABP, Pittsburgh, PA USA

[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA

[8] NSABP Biostat Ctr, Pittsburgh, PA USA

[9] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Natl Surg Adjuvant Breast & Bowel Project,Biostat, Pittsburgh, PA 15261 USA

[10] NSABP, Washington, DC USA

[11] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[12] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[13] Allegheny Gen Hosp, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15212 USA

[14] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1139

引用

页数：1

共 50 条

[41] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Tolaney, Sara M.
Fallowfield, Lesley
Kaufman, Peter A.
Ciruelos, Eva M.
Gainford, Mary Corona
Lu, Yi
Hurt, Karla
Wasserstrom, Heather Ann
Chen, Yanyun
Goel, Shom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer
Criscitiello, Carmen
Disalvatore, Davide
De Laurentiis, Michele
Gelao, Lucia
Fumagalli, Luca
Locatelli, Marzia
Bagnardi, Vincenzo
Rotmensz, Nicole
Esposito, Angela
Minchella, Ida
De Placido, Sabino
Santangelo, Michele
Viale, Giuseppe
Goldhirsch, Aron
Curigliano, Giuseppe
BREAST, 2014, 23 (01): : 69 - 75
[43] Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
Karlsson, P.
Sun, Z.
Braun, D.
Price, K. N.
Castiglione-Gertsch, M.
Rabaglio, M.
Gelber, R. D.
Crivellari, D.
Collins, J.
Murray, E.
Zaman, K.
Colleoni, M.
Gusterson, B. A.
Viale, G.
Regan, M. M.
Coates, A. S.
Goldhirsch, A.
ANNALS OF ONCOLOGY, 2011, 22 (10) : 2216 - 2226
[44] Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
Jänicke, F
Prechtl, A
Thomssen, C
Harbeck, N
Meisner, C
Untch, M
Sweep, CGJF
Selbmann, HK
Graeff, H
Schmitt, M
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (12) : 913 - 920
[45] Comparison of Survival Outcomes in Node-Negative T1a and T1b High-risk Breast Cancer Treated with and without Adjuvant Chemotherapy
Carlson, K. A.
Thompson, C. K.
Siegel, E. L.
Kim, S.
Bao, J. J.
Amersi, F.
Giuliano, A.
Chung, A.
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S98 - S98
[46] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston, Stephen R. D.
Harbeck, Nadia
Hegg, Roberto
Toi, Masakazu
Martin, Miguel
Shao, Zhi Min
Zhang, Qing Yuan
Martinez Rodriguez, Jorge Luis
Campone, Mario
Hamilton, Erika
Sohn, Joohyuk
Guarneri, Valentina
Okada, Morihito
Boyle, Frances
Neven, Patrick
Cortes, Javier
Huober, Jens
Wardley, Andrew
Tolaney, Sara M.
Cicin, Irfan
Smith, Ian C.
Frenzel, Martin
Headley, Desiree
Wei, Ran
San Antonio, Belen
Hulstijn, Maarten
Cox, Joanne
O'Shaughnessy, Joyce
Rastogi, Priya
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
[47] Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Geyer, Charles E., Jr.
Bandos, Hanna
Rastogi, Priya
Jacobs, Samuel A.
Robidoux, Andre
Fehrenbacher, Louis
Ward, Patrick J.
Polikoff, Jonathan
Brufsky, Adam M.
Provencher, Louise
Paterson, Alexander H. G.
Hamm, John T.
Carolla, Robert L.
Baez-Diaz, Luis
Julian, Thomas B.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (03) : 555 - 564
[48] Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Charles E. Geyer
Hanna Bandos
Priya Rastogi
Samuel A. Jacobs
André Robidoux
Louis Fehrenbacher
Patrick J. Ward
Jonathan Polikoff
Adam M. Brufsky
Louise Provencher
Alexander H. G. Paterson
John T. Hamm
Robert L. Carolla
Luis Baez-Diaz
Thomas B. Julian
Sandra M. Swain
Eleftherios P. Mamounas
Norman Wolmark
Breast Cancer Research and Treatment, 2022, 193 : 555 - 564
[49] Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)
Loi, S.
Johnston, S.
Arteaga, C.
Graff, S.
Chandarlapaty, S.
Goetz, M.
Desmedt, C.
Sasano, H.
Liu, D.
Rodrik-Outmezguine, V.
Sireci, A.
Sandoval, C.
Won, H.
Litchfield, L.
Turner, N.
BREAST, 2025, 80
[50] Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Loi, Sherene
Johnston, Stephen R. D.
Arteaga, Carlos L.
Graff, Stephanie L.
Chandarlapaty, Sarat
Goetz, Matthew P.
Desmedt, Christine
Sasano, Hironobu
Liu, Deli
Rodrik-Outmezguine, Vanessa
Sireci, Anthony
Sandoval, Cynthia
Won, Helen H.
Litchfield, Lacey M.
Turner, Nicholas C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA507 - LBA507

← 1 2 3 4 5 →